PBYI News and Press, Puma Biotechnology Inc From 09/03/20

MONTREAL, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced filing of the Supplement to a New Drug Submission (SNDS) of NERLYNX for HER2-Positive Metastatic Breast Cancer in Canada. NERLYNX...

Puma Biotechnology (NASDAQ: PBYI ) reports positive preliminary results from an open-label Phase 2 clinical trial, CONTROL , evaluating certain approaches to mitigating diarrheal toxicity associated with breast cancer med neratinib, the most common treatment-related adverse event. The d...

- CONTROL Trial Investigates Anti-diarrheal Strategies Including Dose Escalation in Neratinib-treated Patients with Early Stage HER2-positive Breast Cancer - Dose Escalation Resulted in Reduced Rate, Severity and Duration of Grade ≥ 3 Diarrhea Compared to Phase III ExteNET Tria...

Puma Biotechnology ( PBYI ) has been one of my more frustrating investments over the past year. I decided to take a stab at PBYI in Q4 of 2019 in anticipation the company was going to address NERLYNX’s tolerability and discontinuation rate. Well, the company has started to address these...

The following slide deck was published by Puma Biotechnology, Inc. in conjunction with their 2020 Q2 earnings Read more ...

Image source: The Motley Fool. Puma Biotechnology Inc   (NASDAQ: PBYI) Q2 2020 Earnings Call Aug 6, 2020 , 4:30 p.m. ET Operator Continue reading

Puma Biotechnology, Inc. (PBYI) Q2 2020 Earnings Conference Call August 6, 2020 16:30 ET Company Participants Mariann Ohanesian - Senior Director of Investor Relations Alan Auerbach - Chief Executive Officer, President & Chairman of the Board Jeff Ludwig - Chief Commercial Of...

Puma Biotechnology (NASDAQ: PBYI ) : Q2 Non-GAAP EPS of $0.35 beats by $0.20 ; GAAP EPS of $0.08 beats by $0.38 . More news on: Puma Biotechnology, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2020. Unless otherwise stated, all comparisons are for the second quarter of 2020 compared to the second quarter of 2019. Product revenue, net consists e...

Data published online in Gynecologic Oncology Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that data from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the safety and efficacy of neratinib in HER2 -mutated cancers, ...